{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["99(1)"],"submitter":["Scheid C"],"pubmed_abstract":["Renal impairment is frequent in patients with multiple myeloma and is correlated with an inferior prognosis. This analysis evaluates the prognostic role of renal impairment in patients with myeloma treated with bortezomib before and after autologous stem cell transplantation within a prospective randomized phase III trial. Eight hundred and twenty-seven newly diagnosed myeloma patients in the HOVON-65/GMMG-HD4 trial were randomized to receive three cycles of vincristine, adriamycin, dexamethasone (VAD) or bortezomib, adriamycin, dexamethasone (PAD) followed by autologous stem cell transplantation and maintenance with thalidomide 50 mg daily (VAD-arm) or bortezomib 1.3 mg/m(2) every 2 weeks (PAD-arm). Baseline serum creatinine was less than 2 mg/dL (Durie-Salmon-stage A) in 746 patients and"],"journal":["Haematologica"],"pagination":["148-54"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4007933"],"repository":["biostudies-literature"],"pubmed_title":["Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial."],"pmcid":["PMC4007933"],"pubmed_authors":["Pfreundschuh M","Blau IW","Peter N","Schmidt-Wolf IG","Duehrsen U","Wittebol S","Hanel M","Martin H","Bos GM","Kersten MJ","Vellenga E","Lokhorst HM","van de Velde H","Sonneveld P","Jie KS","Weisel K","Croockewit S","van Marwijk-Kooy M","van der Holt B","Salwender H","Scheid C","Schaafsma MR","Neben K","el Jarari L","Goldschmidt H","Wijermans P","Lindemann W","Zweegman S","Bertsch U"],"additional_accession":[]},"is_claimable":false,"name":"Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.","description":"Renal impairment is frequent in patients with multiple myeloma and is correlated with an inferior prognosis. This analysis evaluates the prognostic role of renal impairment in patients with myeloma treated with bortezomib before and after autologous stem cell transplantation within a prospective randomized phase III trial. Eight hundred and twenty-seven newly diagnosed myeloma patients in the HOVON-65/GMMG-HD4 trial were randomized to receive three cycles of vincristine, adriamycin, dexamethasone (VAD) or bortezomib, adriamycin, dexamethasone (PAD) followed by autologous stem cell transplantation and maintenance with thalidomide 50 mg daily (VAD-arm) or bortezomib 1.3 mg/m(2) every 2 weeks (PAD-arm). Baseline serum creatinine was less than 2 mg/dL (Durie-Salmon-stage A) in 746 patients and","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Jan","modification":"2025-04-05T10:37:45.418Z","creation":"2019-03-27T01:27:30Z"},"accession":"S-EPMC4007933","cross_references":{"pubmed":["23996482"],"doi":["10.3324/haematol.2013.087585"]}}